Mandate

Vinge has advised Annehem Fastigheter AB (publ) in connection with its rights issue

Vinge has advised Annehem Fastigheter AB (publ) in connection with its rights issue of Class A and B shares, which provides Annehem with issue proceeds of approximately SEK 300 million before deduction of transaction costs.

The new Class B shares issued in the rights issue are expected to be admitted to trading on Nasdaq Stockholm on or around 13 March 2024. Annehem Fastigheter is a growth-driven property company specializing in commercial, community service and residential properties in the Nordic growth regions of Stockholm, Skåne, Gothenburg and Helsinki. The property portfolio in Annehem Fastigheter consists of 26 investment properties with a value of SEK 4,412.7 million and a lettable area of 202 thousand sqm as of 31 December 2023. The company's Class B shares are listed on Nasdaq Stockholm.

Vinge’s team consisted primarily of Rikard Lindahl, Joel Magnusson, Oskar Nilsson, Michaela Ådén and Lovisa Jonassen.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024